The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)
Acute myeloid leukemia (AML) is nearly always a fatal malignancy. For the past 40 years, the standard of care remains a combination of cytarabine and an anthracycline known as 7 + 3. This treatment regimen is troubled by both low survival rates (10% at 5 years) and deaths due to toxicity. Substantia...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
MDPI
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712735/ |